Albuterol / Ipratropium is a combination medication used for the treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It contains two active ingredients: albuterol, a bronchodilator that relaxes the muscles in the airways to improve airflow, and ipratropium, an anticholinergic agent that works by blocking the action of acetylcholine, a neurotransmitter that causes constriction of the airways. Albuterol / Ipratropium is available in inhalation solution and inhalation aerosol formulations, providing rapid and effective relief from symptoms of COPD.

One of the standout features of albuterol / ipratropium is its dual mechanism of action, which targets both the bronchoconstriction and inflammation associated with COPD. By opening up the airways and reducing bronchospasm, it helps improve breathing and reduce symptoms such as wheezing, shortness of breath, and coughing. Additionally, albuterol / ipratropium offers the convenience of combination therapy in a single inhaler device, simplifying medication management and ensuring optimal delivery of both medications to the lungs.